These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 14968337)

  • 41. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
    Sever PS; Poulter NR; Dahlof B; Wedel H;
    J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin.
    Murrow JR; Sher S; Ali S; Uphoff I; Patel R; Porkert M; Le NA; Jones D; Quyyumi AA
    J Clin Lipidol; 2012; 6(1):42-9. PubMed ID: 22264573
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early outcome of acute ischemic stroke in hyperlipidemic patients under atorvastatin versus simvastatin.
    Lampl Y; Lorberboym M; Gilad R; Vysberg I; Tikozky A; Sadeh M; Boaz M
    Clin Neuropharmacol; 2010 May; 33(3):129-34. PubMed ID: 20502132
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
    Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
    Drugs; 2004; 64 Suppl 2():43-60. PubMed ID: 15765890
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
    Schuster H; Barter PJ; Stender S; Cheung RC; Bonnet J; Morrell JM; Watkins C; Kallend D; Raza A;
    Am Heart J; 2004 Apr; 147(4):705-13. PubMed ID: 15077101
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Statins: new data in secondary prevention and diabetes. Pravastatin and simvastatin are the best-assessed statins.
    Prescrire Int; 2003 Aug; 12(66):143-8. PubMed ID: 12908497
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
    Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
    Smith DG; McBurney CR
    Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study).
    Nicholls SJ; Tuzcu EM; Sipahi I; Schoenhagen P; Hazen SL; Ntanios F; Wun CC; Nissen SE
    Am J Cardiol; 2006 Jun; 97(11):1553-7. PubMed ID: 16728212
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
    Pearson T; Ballantyne C; Sisk C; Shah A; Veltri E; Maccubbin D
    Am J Cardiol; 2007 Jun; 99(12):1706-1713. PubMed ID: 17560879
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hypothesis: atorvastatin has pleiotropic effects that translate into early clinical benefits on cardiovascular disease.
    Novela C; Hennekens CH
    J Cardiovasc Pharmacol Ther; 2004 Mar; 9(1):61-3. PubMed ID: 15094970
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
    McKenney JM; Jones PH; Adamczyk MA; Cain VA; Bryzinski BS; Blasetto JW;
    Curr Med Res Opin; 2003; 19(8):689-98. PubMed ID: 14687438
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of atorvastatin on peripheral endothelial function and systemic inflammatory markers in patients with stable coronary artery disease.
    Alber HF; Frick M; Süssenbacher A; Dörler J; Dichtl W; Stocker EM; Pachinger O; Weidinger F
    Wien Med Wochenschr; 2007 Feb; 157(3-4):73-8. PubMed ID: 17340064
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled for percutaneous coronary intervention.
    Ishii H; Nishio M; Takahashi H; Aoyama T; Tanaka M; Toriyama T; Tamaki T; Yoshikawa D; Hayashi M; Amano T; Matsubara T; Murohara T
    Clin Ther; 2010 Dec; 32(14):2337-47. PubMed ID: 21353104
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systemic atherosclerosis risk and the mandate for intervention in atherosclerotic peripheral arterial disease.
    Criqui MH
    Am J Cardiol; 2001 Oct; 88(7B):43J-47J. PubMed ID: 11595199
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
    Tikkanen MJ; Holme I; Cater NB; Szarek M; Faergeman O; Kastelein JJ; Olsson AG; Larsen ML; Lindahl C; Pedersen TR;
    Am J Cardiol; 2009 Mar; 103(5):577-82. PubMed ID: 19231315
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
    Kastelein JJ; van Leuven SI; Burgess L; Evans GW; Kuivenhoven JA; Barter PJ; Revkin JH; Grobbee DE; Riley WA; Shear CL; Duggan WT; Bots ML;
    N Engl J Med; 2007 Apr; 356(16):1620-30. PubMed ID: 17387131
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease.
    Alnaeb ME; Youssef F; Mikhailidis DP; Hamilton G
    Angiology; 2006; 57(1):65-71. PubMed ID: 16444458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.